openPR Logo
Press release

Biosimilar Monoclonal Antibody Market Size will growing at 35.70% CAGR to 2026| Allergan plc, BIOCAD BioXpress, Therapeutics SA, Biocon Limited, Boehringer Ingelheim GmbH, Celltrion Inc, Coherus BioSciences Inc

05-20-2020 06:49 PM CET | Health & Medicine

Press release from: marketstudyreport.com

/ PR Agency: marketstudyreport.com
Biosimilar Monoclonal Antibody Market

Biosimilar Monoclonal Antibody Market

Biosimilar monoclonal antibodies can be known as a biological molecule derived by the organisms and living cells. Also, it displays a certain level of variability which can be attributed to the variations in the biological expression systems of the recombinant. In addition, biosimilar monoclonal antibodies are widely used in various fields of diagnostics of diseases such as oncology, autoimmune and in various chronic diseases. Global Biosimilar Monoclonal Antibody Market is valued approximately at USD 27.84 Billion in 2018 and is anticipated to grow with a healthy growth rate of more than 35.70% over the forecast period 2019-2026.

Request a sample Report of Biosimilar Monoclonal Antibody Market at: https://www.marketstudyreport.com/request-a-sample/2570987/?utm_source=OPR.com/&utm_medium=SP

The Biosimilar Monoclonal Antibody market to witness prominent growth owing to the incorporation of advanced mAbs (Monoclonal Antibodies). As a result, the demand & adoption for Biosimilar Monoclonal Antibody would increase thereby, making its way for the growth of the market. The growth of the market is primarily driven by the increase in prevalence of diseases, such as cancer and rheumatoid arthritis and growth in geriatric population globally.

For Instance: according to World Cancer Research Fund International (WCRFI), breast cancer is the most common form of cancer in women worldwide with an average 2million new cases being detected every year.

American Cancer Research Society (ACRS) anticipates by 2030, incident rate of breast cancer is expected to reach over 9.9million cases with over 5.5million annual deaths, primarily due to aging population. Similarly, as per the European Breast Cancer Coalition, incidence in the EU-28 in 2018 was estimated to be around 404,920. Thus, the demand for biosimilar monoclonal antibodies would increase as these drugs are normally administered in the treatment of cancer, chronic lymphocytic and leukemia. However, unfavorable government regulations in developed regions along with the high cost associated with the manufacturing process of these drugs are expected to impede the growth of the market over the forecast period.

Major market player included in this report are:
o Allergan plc
o BIOCAD BioXpress
o Therapeutics SA
o Biocon Limited
o Boehringer Ingelheim GmbH
o Celltrion Inc
o Coherus BioSciences Inc
o Dr. Reddys Laboratories Ltd
o Genor BioPharma Co Ltd
o Intas Pharmaceuticals Limited

The regional analysis of global Biosimilar Monoclonal Antibody market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World. North America is expected to hold a notable share in the world in terms of revenue owing to the presence of advanced healthcare facilities along with the increasing adoption of biosimilar monoclonal antibodies. The dominance of the region is witnessed owing to the ongoing government activities to develop advanced and novel drugs. Whereas, Asia-Pacific is also anticipated to exhibit highest growth rate / CAGR over the forecast period. Factors such as rising public-private initiative aimed towards boosting advance research practices and increase investment to promote Biosimilar Monoclonal Antibody research is expected to create lucrative prospects for the growth pf the region during the forecast period of 2019-2026.

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:
By Type:
o Synthetic Chemicals
o Biopharmaceuticals
o Others

By Application:
o Chronic & Autoimmune Diseases
o Oncology
o Others

Table of Contents:

Chapter 1. Executive Summary
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2017-2026 (USD Billion)
1.2.1. Biosimilar Monoclonal Antibody Market, by Region, 2017-2026 (USD Billion)
1.2.2. Biosimilar Monoclonal Antibody Market, by Type, 2017-2026 (USD Billion)
1.2.3. Biosimilar Monoclonal Antibody Market, by Application, 2017-2026 (USD Billion)
1.2.4. Biosimilar Monoclonal Antibody Market, by End-User, 2017-2026 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global Biosimilar Monoclonal Antibody Market Definition and Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global Biosimilar Monoclonal Antibody Market Dynamics
3.1. Biosimilar Monoclonal Antibody Market Impact Analysis (2018-2026)
3.1.1. Market Drivers
3.1.2. Market Challenges
3.1.3. Market Opportunities
Chapter 4. Global Biosimilar Monoclonal Antibody Market: Industry Analysis
4.1. Porter's 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter's 5 Force Model (2016-2026)
4.2. PEST Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.3. Investment Adoption Model
4.4. Analyst Recommendation & Conclusion
Chapter 5. Global Biosimilar Monoclonal Antibody Market, by Type
Chapter 6. Global Biosimilar Monoclonal Antibody Market, by Application
Chapter 7. Global Biosimilar Monoclonal Antibody Market, Regional Analysis
Chapter 8. Global Biosimilar Monoclonal Antibody Market Competitive Intelligence

Ask for Discount on Biosimilar Monoclonal Antibody Market Report at: https://www.marketstudyreport.com/check-for-discount/2570987/?utm_source=OPR.com/&utm_medium=SP

Contact Us:
Market Study Report LLC,
4 North Main Street,
Selbyville, Delaware 19975
USA
Phone: 1-302-273-0910
US Toll Free: 1-866-764-2150
Email: sales@marketstudyreport.com
Website: www.marketstudyreport.com
Blog: www.marketstudyreport.com/

About Us:
Marketstudyreport.com allows you to manage and control all corporate research purchases to consolidate billing and vendor management. You can eliminate duplicate purchases and customize your content and license management.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Biosimilar Monoclonal Antibody Market Size will growing at 35.70% CAGR to 2026| Allergan plc, BIOCAD BioXpress, Therapeutics SA, Biocon Limited, Boehringer Ingelheim GmbH, Celltrion Inc, Coherus BioSciences Inc here

News-ID: 2052975 • Views: 507

More Releases from marketstudyreport.com

Covid -19 Impact on Video Conferencing Market Size 2026: Top Companies, Trends a …
Market Study Report recently introduced new title on “2020-2026 Global Video Conferencing Market Report” from its database. The report provides study with in-depth overview, describing about the Product, Industry Scope and elaborates Market size outlook and status to 2026. Video Conferencing Market size is anticipated to grow at over 19% CAGR between 2020 and 2026. The global video conferencing market is set to register a tremendous rise in its growth
What's driving the Patient Monitoring Devices Market Size? Fukuda, Philips, Skan …
Selbyville, Delaware the prime objective of Patient Monitoring Devices report is to help the user understand the market in terms of its definition, segmentation, market potential, influential trends, and the challenges that the market is facing. Deep researches and analysis were done during the preparation of the report. Wireless segment is anticipated to witness more than 5% growth over the forecast period. Substantial growth can be attributed to rising preference for
What's driving the 3D Implants Market trends? Stryker, Smith and Nephew, DJO Glo …
The 3D Implants market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations. Request a sample Report of 3D Implants Market at: https://www.marketstudyreport.com/request-a-sample/2679238/?utm_source=OPR.com/&utm_medium=SP The most likely (base case) scenario
Artificial Vascular Implants Market is thriving worldwide by 2025 | Top Key Play …
Global Artificial Vascular Implants Market Report added at Market Study Report LLC offers industry size, share, growth, trends and forecast analysis up to 2025. Artificial Vascular Implants Market Report also covers top key players, porters five forces analysis and market segmentation in detail. This report examines the global Artificial Vascular Implants market and provides information regarding the revenue for the period 2020 to 2025. The Artificial Vascular Implants market report provides

All 5 Releases


More Releases for Biosimilar

Global Biosimilar Drug Sales Market Report 2018
In this report, the global Biosimilar Drug market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025. Free | Request Sample Copy of the Report @ https://bit.ly/2M8e47Z Geographically, this report split global into several key Regions, with sales (K MT), revenue (Million USD), market share and growth rate of Biosimilar Drug for
Biosimilar Insulin Market Access
Boston, MA ReportsWorldwide has announced the addition of a new report title Biosimilar Insulin Market Access to its growing collection of premium market research reports. Biosimilar competition is providing payers with opportunities to contain costs in a category that accounts for a significant proportion of total drug expenditure. The launch of the biosimilar insulin Basaglar is a threat to the insulin-based product market, which includes long-time reference product Lantus as well as newer
Biosimilar Insulin Market Access
ReportsWorldwide has announced the addition of a new report title Biosimilar Insulin Market Access to its growing collection of premium market research reports. Biosimilar competition is providing payers with opportunities to contain costs in a category that accounts for a significant proportion of total drug expenditure. The launch of the biosimilar insulin Basaglar is a threat to the insulin-based product market, which includes long-time reference product Lantus as well as newer entrants
Biosimilar Insulin Market Biosimilar Insulin Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents Prologue to Insulin Biosimilars 1.1 Outline Towards Insulin 1.2 Trail of Insulin Evolution and Development Rationale Design of Insulin Molecule 2.1 Structure of Insulin Polypeptide 2.2 Biosynthesis of Insulin 2.3 Secretion of Insulin Mechanism of Insulin in Diabetics 3.1 Glucose Metabolism of Insulin 3.2 Impact of Insulin Dysregulation in Diabetes 1 3.3 Impact
Herceptin (Trastuzumab) Biosimilar Clinical Trial Insight
“Herceptin (Trastuzumab) Biosimilar Clinical Trial Insight” report by PNS Pharma gives comprehensive clinical insight on 37 biosimilar version of Herceptin drug in clinical pipeline. Currently there are 4 biosimilars in Phase-III trials and are expected to be commercially available in next 5-8 years. Currently 3 biosimilar version of Herceptin are commercially available in India and Iran for the treatment of Breast cancer. The patent on Herceptin expired in 2014. Trastuzumab or
India Biosimilar Market Analysis
As the number of patent expiries of biologic drugs is increasing, Indian companies are developing biosimilar manufacturing capabilities. Firms are developing their capabilities by either forming partnerships with R&D-intensive firms or outsourcing to upcoming Indian contract research organizations (CROs). Domestic manufacturers have a cost advantage (lower facility and development costs) than peers in developed countries. Moreover, Indian firms seem keen on repeating their successes achieved in developing and commercializing biosimilars.